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Spontaneous binding of infected erythrocytes to uninfected erythrocytes to form rosettes is a property of
some strains of Plasmodium falciparum that is linked to severe complications of malaria. Curdlan sulfate
(CRDS) is a sulfated glycoconjugate compound that is chemically similar to known rosette-inhibiting drugs
such as heparin. CRDS has previously been shown to have antimalarial activity in vitro and is safe for clinical
use. Here we show that CRDS at therapeutic levels (10 to 100 g/ml) significantly reduces rosette formation
in vitro in seven P. falciparum laboratory strains and in a group of 18 African clinical isolates. The strong
ability to inhibit rosetting suggests that CRDS has the potential to reduce the severe complications and
mortality rates from P. falciparum malaria among African children. Our data support further clinical trials of
CRDS.
Despite decades of research, malaria still claims an esti-
mated 1 million lives per year in sub-Saharan Africa, and
severe complications, such as cerebral malaria, remain rela-
tively common (19). Treatment for malaria involves the use of
antimalarial drugs that kill the parasite, along with supportive
measures, such as the provision of intravenous fluids and blood
transfusion as required. Progress in understanding the patho-
genesis of malaria has led to the possibility of designing ther-
apies that target factors that contribute to severe disease in
order to ameliorate the clinical complications and reduce the
number of deaths from malaria.
Rosetting is the spontaneous binding of noninfected eryth-
rocytes to erythrocytes infected with mature asexual blood-
stage Plasmodium parasites (reviewed in reference 14). In Plas-
modium falciparum malaria, rosetting is associated with high
levels of parasitemia (16) and with disease severity in African
children (13, 17), especially cerebral malaria (2). Other Plas-
modium species also rosette, although it is only in P. falciparum
that rosetting is linked to severe disease, probably because of
the additional cytoadhesion properties that may act in concert
with rosetting to cause microvascular obstruction (8, 14). Ro-
setting in P. falciparum is mediated by heterogeneous mecha-
nisms involving specific members of the parasite variant anti-
gen family PfEMP1 (15), which are expressed on the surface of
infected erythrocytes and which binding to a variety of recep-
tors on uninfected red cells, such as complement receptor 1
(CR1), heparan sulfate-like sugars, and ABO blood group
oligosaccharides (reviewed in reference 14).
Previous work has shown that rosettes can be disrupted by
sulfated glycoconjugate compounds such as heparin and fu-
coidan (1, 12), but the anticoagulant effects of these drugs
prevent their use as treatments for severe malaria (19). Curd-
lan sulfate (CRDS; a semisynthetic sulfated 133--D-glucan)
has been shown to inhibit P. falciparum invasion in vitro (6)
and is safe for use by adult patients with severe malaria (5). It
was hypothesized that CRDS might be effective against P.
falciparum rosetting (5) because of the chemical similarities
between CRDS and heparin (7). The 10-fold lower anticoag-
ulant effect of CRDS compared to the effect of heparin makes
it a more suitable candidate than heparin as an adjunctive
treatment for severe malaria (5). In this study we have tested
the ability of CRDS to inhibit rosetting in P. falciparum labo-
ratory strains and clinical isolates and show strong rosette-
inhibiting activity at therapeutic doses of CRDS.
MATERIALS AND METHODS
Parasites. The laboratory strains studied were TM284, TM180, HB3R, R29,
Muz12R, PAR, and A4R. Apart from R29, A4R, and PAR, these strains
are genetically distinct; R29, A4R, and PAR are clones derived from strain
IT/FCR3. The three IT/FCR3-derived clones express different PfEMP1 variants
(15; J. A. Rowe, unpublished data) and therefore form rosettes via distinct
molecular mechanisms and can thus be considered independent parasite lines.
The parasites were cultured in RPMI 1640 medium plus 25 mM HEPES, 2 mM
glutamine, 25 mM glucose, 25 g/ml gentamicin, and 10% pooled human serum.
Cultures were maintained at approximately 2% hematocrit in blood group O red
blood cells with normal CR1 levels at 5 to 10% parasitemia and were incubated
at 37°C and gassed with 3% CO2, 1% O2, and 96% N2. The cultures were
synchronized once a week by sorbitol lysis. Laboratory strains were maintained
at a rosette frequency (RF; percentage of mature pigmented infected erythro-
cytes that bind to two or more uninfected erythrocytes) of 40% or higher by using
Percoll or Plasmagel to enrich for rosetting parasites twice a week. Clinical
isolates were collected from children with malaria at Kilifi District Hospital,
Kenya, after informed consent was obtained from the patients’ parents or guard-
ians. Three clinical isolates were analyzed as fresh samples, and 15 clinical
isolates were frozen (10 at the ring stage and 5 at the pigmented trophozoite
stage). The fresh clinical isolates were cultured for at least 18 h in vitro to the
mature pigmented trophozoite stage as described above, except that pooled
human group AB serum was used. Frozen ring- and trophozoite-stage clinical
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isolates were cryopreserved in glycerolyte and were stored in liquid nitrogen
before they were thawed for either immediate use (frozen trophozoites) or
culture to the mature pigmented trophozoite stage (frozen rings). Cryo-
preservation of mature trophozoites does not affect the surface antigens of
the trophozoite-infected erythrocytes (9), and an isolate’s RF does not
change significantly prefreezing and postthawing, as long as the sample is
mixed thoroughly postthawing (data not shown). A summary of the clinical
isolates used and their baseline RFs is as follows (Fzt, frozen trophozoites;
Fzr, frozen rings; Fsh, fresh peripheral blood sample): 6394Fzt, RF 15%;
6399Fzt, RF 12%; 6457Fzt, RF 5%; 6542Fzt, RF 52%; 6566Fzt, RF 48%;
6794Fzr, RF 33%; 6908Fsh, RF 27%; 6921Fsh, RF 27.5%; 6962Fsh, RF
24.5%; KR1Fzr, RF 53.5%; KR7Fzr, RF 68%; KR9Fzr, RF 14%; KR10Fzr,
RF 25%; KR11Fzr, RF 27%; KR14Fzr, RF 37.5%; KR17Fzt, RF 61%;
KR18Fzt, RF 28%; and KR20Fzr, RF 63%.
Effect of CRDS on rosetting. All rosette disruption assays were performed with
mature pigmented trophozoites, as determined by a Giemsa smear. The parasites
were resuspended at 2% hematocrit in complete binding medium (sodium bi-
carbonate-free RPMI 1640 supplemented as described above for the culture
medium). The culture suspension was prestained with ethidium bromide or
acridine orange to identify infected erythrocytes. These staining methods do not
alter the RF. CRDS was obtained from the Ajinomoto Co Inc., Tokyo, Japan
(average molecular mass, 70 kDa; batch no. G2102; sulfur content, 14.6% [wt/
wt]) and was dissolved in sterile phosphate-buffered saline (PBS). Two microli-
ters of an appropriate dilution of the drug in PBS was added to 18 l of culture
suspension to give final concentrations of 0, 10, 50, and 100 g/ml of CRDS.
Final concentrations of 100 g/ml fucoidan and 100 g/ml hyaluronic acid (both
from Sigma, United Kingdom) were used as positive and negative controls for
rosette inhibition, respectively (12). The P. falciparum cultures were incubated
with drug for 30 min before assessment of the RF. The laboratory strains were
incubated at 37°C, and the cells were resuspended every 10 min by gently flicking
the tubes. The clinical isolates were rotated for 30 min at room temperature.
Rotation and room temperature incubation do not alter the RF, as tested with
laboratory strain PAR (data not shown). Wet-preparation slides of the cultures
were viewed with a fluorescence microscope. Two hundred infected erythrocytes
were counted, and the percentage that formed rosettes was assessed; an infected
erythrocyte that binds to at least two uninfected erythrocytes constitutes a ro-
sette. All slides were counted blind. For laboratory strains, at least four inde-
pendent experiments were carried out for each strain. The clinical isolates were
tested in a single experiment in the first cycle of growth in vitro. The RF after
addition of drug or PBS (control) was calculated as a proportion of the pretreat-
ment RF, in order to allow comparisons across strains and to determine whether
the addition of PBS (the buffer in which the drugs were solubilized) or the
conditions of the experiment (temperature, agitation, etc.) had any effect on RF.
Effect of CRDS on platelet-mediated clumping. Parasite lines HB3, NF54, and
IT/C10 were cultured by standard methods, as described above. Mature pig-
mented trophozoite-stage parasite cultures were incubated with 25 g/ml of
ethidium bromide at 37°C for 5 min, washed once with RPMI 1640 medium, and
finally suspended at 5% hematocrit in RPMI 1640 medium. Twenty microliters
of platelet-rich plasma, obtained from group O-positive whole blood by centrif-
ugation at 250  g for 10 min, was added to 200 l of the parasite suspension.
The mixture was gently rotated for 1 h. The effect of CRDS on clumping was
assessed by adding the drug either 30 min before or 30 min after the addition of
the platelet-rich plasma (final CRDS concentration, 100 g/ml). Wet prepara-
tions of the different conditions were viewed under a UV microscope, and 750
infected red blood cells were counted and scored for clumping, with 3 or more
infected cells adherent to each other constituting a clump. The clumping fre-
quency (CF) was calculated as the percentage of infected erythrocytes in clumps
of 750 infected erythrocytes counted.
Statistical analysis. Statistical analysis was carried out with Statview 5.0.1
software (SAS Institute Inc., Cary, NC). For both the laboratory strains and the
clinical isolates, posttreatment RFs were first converted to a relative RF (calcu-
lated as a proportion of each isolate’s own pretreatment RF), and then the effects
of drug were compared to that of the PBS control (0 g/ml CRDS) by paired t
test. Additional analysis by analysis of variance gave similar results (data not
shown).
RESULTS AND DISCUSSION
The effect of CRDS on P. falciparum rosetting was tested
with seven distinct laboratory parasite strains that had been
selected for their high levels of rosetting (strains PAR, A4R,
R29, TM284, TM180, Muz12R, and HB3R). Three con-
centrations of CRDS (10, 50, and 100 g/ml) were used, along-
side a PBS control (i.e., 0 g/ml CRDS). The plasma level of
CRDS after treatment at therapeutic doses (4 mg/kg) is esti-
mated to be approximately 50 to 60 g/ml (Investigator Man-
ual, Aji Pharma, 1995, unpublished data). By combining the
data for all seven parasite strains, a strong inhibitory effect of
CRDS was seen at all three concentrations of drug (for the
PBS control, the mean RF was 62.3% and the standard error
[SE] was 2.8%; for 10 g/ml CRDS, the mean RF was 21.9%
and the SE was 6.6%; for 50 g/ml CRDS, the mean RF was
14.6% and the SE was 4.6%; and for 100 g/ml CRDS, the
mean RF was 8.7% and the SE was 2.7% [P  0.005 for each
concentration of drug compared to the results obtained with
PBS, paired t test]). As expected (12), fucoidan provided a
reliable positive control for rosette inhibition (mean RF, 5.4%;
SE, 1.0%) and hyaluronic acid provided a reliable negative
control (mean RF, 65.2%; SE, 2.8%).
By examining the data for each parasite strain indepen-
dently, it was found that all seven strains responded to CRDS
in a concentration-dependent manner, although there was
some variation in the response between strains (Fig. 1A). Ro-
setting was significantly reduced (P  0.05, paired t test) by
CRDS at both 100 g/ml and 50 g/ml in all parasite strains
(Fig. 1A). At 10 g/ml CRDS, RF was significantly reduced for
five of seven parasite strains (Fig. 1A and B). It is unclear why
some strains, such as PAR, are very sensitive to CRDS, with
complete inhibition of rosetting at 10 g/ml of drug (Fig. 1A
and B), whereas others, such as TM284, require higher doses
for significant inhibition of rosetting (Fig. 1A). This may be
due to heterogeneity in the molecular mechanisms of rosetting
in distinct strains (reviewed in reference 14), resulting in dif-
ferences in the strengths of the rosettes between strains. The
mechanism of action of CRDS is unclear, that is, whether it
inhibits rosetting by interacting nonspecifically with all unin-
fected red cells or whether it interacts specifically with infected
erythrocytes. Further experiments investigating the mechanism
of action of CRDS on rosetting may shed light on the reasons
for the differences in strain sensitivity.
To test the speed of action of CRDS, PAR (mean RF,
70%; SE, 4.0%) was treated with 50 g/ml of drug and the RF
was recorded over 2 h (at 0, 2, 5, 30, 60, and 120 min after drug
addition). Rosettes were disrupted within 2 min and remained
disrupted for up to 2 h after drug addition (Fig. 1A, PAR
Kinetics). Similarly, with the least CRDS-sensitive strain
TM284, the maximum effect occurred rapidly and was main-
tained for up to 2 h (Fig. 1A, TM284 Kinetics).
Rosette reformation assays were carried out with PAR
parasites. After 30 min of CRDS treatment, the culture was
washed with incomplete binding medium (as binding medium,
but with no added serum) and then resuspended in fresh com-
plete binding medium. The RF returned to 102% (SE, 6.5%)
of the original RF within 2 h. This shows kinetics similar to that
of the fucoidan-treated cultures (12), which return to 100% of
the original RF (SE, 8.2%) after they are washed.
We also tested the ability of 100 g/ml of CRDS to inhibit
another P. falciparum adhesion phenomenon, the platelet-me-
diated clumping of infected erythrocytes (11). By using labo-
ratory parasite strain HB3 in three independent experiments,
the mean CF (percentage of infected erythrocytes in clumps of
three or more infected erythrocytes) in the PBS control culture
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FIG. 1. Inhibition of rosetting by CRDS in laboratory strains of P. falciparum. (A) Parasite cultures were treated for 30 min with 0 g/ml CRDS
(PBS control), 10 g/ml CRDS (CRDS10), 50 g/ml CRDS (CRDS50), 100 g/ml CRDS (CRDS100), 100 g/ml fucoidan (positive control), or
100 g/ml hyaluronic acid (HA; negative control). The parasite strain names are shown at the top of each box. Strains PAR and TM284 were
also monitored over 120 min after treatment with 50 g/ml CRDS or the PBS control to examine the kinetics of rosette inhibition by CRDS. Each
graph shows the means  SEs from at least four independent experiments for each parasite strain. The relative RF is calculated as a proportion
of the pretreatment RF to allow comparison across strains and experiments. The pretreatment RF for each strain was stable on a given day but
varied from 40 to 80% of infected erythrocytes in rosettes on different days, depending on factors related to different red blood cell donors and
the timing of selection. , P  0.05 by paired t test compared to the result for the PBS control; , P  0.005 by paired t test compared to the result
for the PBS control. (B) Complete inhibition of rosetting in P. falciparum laboratory strain PAR with 10 g/ml CRDS. For the control culture
(no drug), the RF was 62%; for the culture with 10 g/ml CRDS, the RF was 0%. Live wet-preparation images, viewed with a 40 objective lens
under a bright-field microscope, are shown. Infected erythrocytes can be identified by the presence of black dots of malaria pigment inside the red
blood cells.
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was 38.7% (SE, 8.9%). When CRDS was added after the
platelets were added (see Materials and Methods for full ex-
perimental details), the mean CF was 38.3% (SE, 5.1%), and
when CRDS was added before the platelets were added, the
mean CF was 51.2% (SE, 8.8%) (the difference was not sig-
nificant by paired t tests compared to the results for the PBS
control). Therefore, in contrast to the highly effective rosette
disruption, we found that CRDS caused no disruption of pre-
formed platelet-mediated clumps and was also unable to pre-
vent clumping if it was added before the platelets were added.
FIG. 2. Inhibition of rosetting by CRDS in P. falciparum clinical isolates from Kilifi, Kenya. Field isolates were treated with 0 g/ml CRDS
(PBS); 10, 50, or 100 g/ml CRDS; 100 g/ml fucoidan (positive control); or 100 g/ml hyaluronic acid (HA; negative control). Data are from a
single experiment in the first cycle of in vitro growth for each isolate. Data (means  SEs) are given for all 18 field isolates combined (, P 
0.001 by paired t tests compared to the results for the PBS control) and for each isolate individually. The relative RF is calculated as a proportion
of the pretreatment RF for each isolate. Isolate names are shown at the top of each box. Isolates were collected either as fresh rings (Fshr), frozen
rings (Fzr), or frozen mature trophozoites (Fzt); however, the collection method did not affect sensitivity to CRDS (see the Materials and Methods
and the Results for full details).
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Additional experiments with two other distinct laboratory par-
asite strains (strains NF54 and IT/C10) showed similar results,
with no inhibition of platelet-mediated clumping by CRDS.
Because clumping has previously been shown to be a phenom-
enon mediated at least in part by the platelet receptor CD36
(11), these data are consistent with the results of Evans et al.
(3), who showed that CRDS has no effect on P. falciparum
binding to platelets or CD36. Previous studies have suggested
that platelet-mediated clumping might be another parasite ad-
hesion phenotype, in addition to rosetting, that is associated
with severe malaria (11). If clumping does contribute to the
pathogenesis of severe malaria, the data shown here would
suggest that CRDS would be useful only in cases of severe
malaria associated with rosetting but not in cases associated
with clumping. Our recent data from a case-control study in
Mali suggest that clumping is primarily associated with high
levels of parasitemia and not with disease severity (M. Arman
et al., submitted for publication); therefore, further work will
be required to determine the significance of clumping and the
relevance of the resistance of clumping to CRDS in the treat-
ment of severe malaria.
To investigate further the potential of CRDS as an antiro-
setting treatment for patients with malaria, we tested CRDS (0,
10, 50, and 100 g/ml), alongside fucoidan and hyaluronic acid
as positive and negative controls, respectively, with 18 clinical
isolates collected from children with malaria at Kilifi District
Hospital, Kenya. These were a mixture of fresh and frozen
isolates, and they were cultured to the mature trophozoite
stage in vitro (see Material and Methods). The RF was ex-
pressed relative to the pretreatment RF, so that all 18 clinical
isolates could be compared. All isolates responded to CRDS;
and there was a significant inhibition (P  0.001) across all
field isolates combined by treatment with CRDS at 10, 50, and
100 g/ml (Fig. 2). As with the laboratory strains, there was
evidence of high and low responders to CRDS, with some
isolates reacting strongly to a low dose, whereas others re-
quired the highest dose for rosette disruption (Fig. 2). Of the
18 clinical isolates tested, 4 isolates showed 50% rosette
inhibition with only 10 g/ml CRDS, whereas 10 required 50
g/ml CRDS and 2 required 100 g/ml CRDS for 50% rosette
inhibition. The remaining two isolates (isolates 6399Fzt and
KR7Fzr) showed 52% and 70% of the pretreatment RF, re-
spectively, when they were treated with 100 g/ml CRDS. Nine
of the frozen isolates tested (those named KR) were collected
in 1993, and the remaining isolates were collected in 2005 and
2006. CRDS was equally effective against both sets of isolates,
showing that with time there is no change in the rosetting
phenotype that leads to alterations in CRDS sensitivity. There
were also no differences in the CRDS sensitivities of fresh
isolates and frozen isolates.
These data show that CRDS has rosette-inhibiting activity
comparable to that of fucoidan and is active against a broader
range of isolates than heparin, which caused 50% rosette
inhibition in 6/10 isolates (12) and 16/54 isolates (1) in previous
studies. Even at high doses (650 g/ml), heparin had no inhib-
itory effect on rosetting in 23/54 clinical isolates (1). A recent
paper suggested that heparin derivatives that lack anticoagu-
lant activity might be useful as adjunctive therapies for severe
malaria (18). However, because of strain variability in response
to heparin, such heparin derivatives would need to show activ-
ity against a broader range of isolates than the parental com-
pound to be of clinical use.
In conclusion, we have found that CRDS effectively and
consistently disrupts rosetting in 7/7 laboratory strains and in a
group of 18 rosetting field isolates at doses suitable for clinical
use. High levels of rosetting are estimated to occur in approx-
imately 25 to 50% of severe malaria cases in sub-Saharan
Africa (14). Rosette-inhibiting drugs therefore have the poten-
tial to have a substantial impact on malaria mortality and
morbidity in African children. The multiorgan failure type of
severe malaria commonly seen in adults in Southeast Asia is
not associated with high levels of rosetting (reviewed in refer-
ence 14); therefore, CRDS would not be expected to have a
substantial clinical effect resulting from its rosette-inhibiting
properties in this group of patients.
CRDS has already been shown to be safe and well tolerated
in clinical trials for human immunodeficiency virus and malaria
(4, 5). The drug has a short plasma half-life (2 to 3 h) and is
given by intravenous infusion (4); therefore, it is suitable only
for hospital use. A recent clinical trial found that CRDS was
able to reduce the fever clearance time in patients with severe
falciparum malaria in Thailand (5). CRDS is able to inhibit P.
falciparum growth in vitro by inhibiting merozoite invasion (3,
6). In addition CRDS has also been shown to inhibit the pro-
duction of cytokines, such as tumor necrosis factor alpha (10).
Our data on rosette inhibition, together with data from previ-
ous reports, suggest that CRDS is a strong candidate for ad-
junctive therapy in patients with severe malaria, especially in
sub-Saharan Africa, where rosetting is strongly associated with
severe disease.
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